Industry: Cannabis and psychedelics

Cannabis and psychedelics funding

Psychedelic drug developers can tap biotech investors and drugmakers, but licensed cannabis firms still struggle to find and keep a bank. We show investors and lenders how the rules in each market shape your numbers.

  • Rules for each market, checked on official pages and dated
  • Decks, models and lender packs for plant-medicine companies
  • Waveup prepares investor materials for cannabis and psychedelics companies: $3B+ raised for 600+ startups since 2014

In short

What is cannabis and psychedelics funding?

Cannabis and psychedelics funding is the money plant-medicine companies raise: equity, loans, grants and sale proceeds. Psychedelic drug developers raise much like biotechs. State-licensed cannabis businesses have a harder time, because federal law still keeps most banks away. In 2024, only about 1,000 US banks and credit unions reported serving them.

Who it's for
Cannabis operators and brands, psychedelic drug developers and clinics, pre-seed to Series D+
What we build
Investor deck, financial model, lender materials, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 6 November 2026. Sources are under each section.

Can cannabis and psychedelic companies still raise money in 2026?

Yes, but each market draws on different money. Drug developers attract biotech investors and drugmakers, while licensed cannabis operators lean on private lenders.

The opportunity

Federal rules began to move in 2026, and drugmakers are now paying for psychedelic drugs.

  • The DEA opened a hearing on 29 June 2026 on moving all marijuana to Schedule III; no decision yet
  • Lilly closed its purchase of psychedelic drug developer AtaiBeckley in September 2026
  • The SAFE Banking Act, which would shield banks that serve cannabis, returned to Congress in June 2026

The problem

Most US banks still keep away from state-licensed cannabis. Two major card networks, Visa and Mastercard, also bar cannabis purchases.

Market size

How big are these markets, and which rules move them?

The US had 21,760 licensed cannabis businesses at the end of 2025. Three years earlier there were 27,852. Psychedelic medicine is still in trials, so investors value it on data and deals. Four rule changes shape where money goes next:

  • Schedules: since 28 April 2026, state-licensed medical marijuana is Schedule III, while adult-use is still Schedule I
  • Hemp: after one delay, many hemp THC products stop counting as hemp under federal law from 11 December 2026
  • Germany: imports of medical cannabis flowers reached 201.1 tonnes in 2025
  • Psychedelics: an April 2026 executive order called for a Right to Try route to experimental psychedelics, ibogaine included
Germany's medical cannabis flower imports in 2024, in tonnes: Q1 8.1, Q2 11.6, Q3 20.7, Q4 31.7.

Cannabis and psychedelics in 2026, in six numbers

43 of 48

cannabis owners in GAO focus groups had a business bank account, often at a high price

22%

of licensed US cannabis businesses were in California at the end of 2025

47%

of those licensed businesses held a licence to grow, the most common type

33t

of Germany's medical cannabis flower imports came from Canada in 2024

25g

of dried cannabis any adult may carry in Germany under its 2024 law

4 years

after its cannabis law took effect, Germany is due to publish a full review of it

Venture capital

Where does the money for cannabis and psychedelic companies come from?

Psychedelic drug developers raise as biotechs do: venture rounds, stock listings and sales to drugmakers. Licensed cannabis businesses rely more on private lenders and on investors they already know.

Lilly's price for AtaiBeckley: about $2.8 billion in cash at closing, plus up to about $1.0 billion through a CVR.
11%

of insured US banks and credit unions reported serving cannabis businesses in 2024

15%+

interest on loans offered to cannabis owners, as reported in GAO focus groups

6 of 14

cannabis owners who sought government grants or loans got them, GAO found

Who invests in cannabis and psychedelic companies?

Funds that back both markets are rare, so most companies mix investors, specialist banks and buyers. A few names by type. For psychedelic VCs, see our top VCs investing in psychedelic startups.

Investor
Type and base
Companies backed or served
Stage or cheque
Leafy Tunnel
VC for medical cannabis and psychedelics; base not stated on its site
Cantourage, Tactogen, Hoodie Analytics
Not stated
Lionheart Ventures
VC for mental health, including psychedelic medicine; base not stated
2A Biosciences, Clerkenwell Health, Entheos Labs
Not stated
Safe Harbor Financial
Banking and lending platform for cannabis and hemp, US; not a bank
Cheech & Chong's Cannabis Co, Würk, BUDR
$120M lent since 2022
First Citizens Bank
US bank with a cannabis and hemp banking team
3,000+ hemp and cannabis clients, such as Green Leaf Business Solutions
Accounts, plus lending; $150 monthly specialty fee
Eli Lilly
Drugmaker and buyer, US
AtaiBeckley, bought in September 2026
$6.75 a share in cash, plus a CVR

Investor database

Pharma investors in our database

The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by pharma investments

  • Investments by industry

    • Healthtech & Wellness42%
    • Pharma19%
    • Biotech17%
    Rounds
    Pre-seedSeed
    Average cheque
    Not listed
    Based in
    Los Angeles, California, United States

    28 investments in total, 7 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness40%
    • Software & Apps15%
    • Pharma7%
    Rounds
    Pre-seedSeedSeries ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    Dallas, United States
    Invests in
    USA

    88 investments in total, 7 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness49%
    • Biotech20%
    • Pharma14%
    Rounds
    SeedSeries A
    Average cheque
    Not listed
    Based in
    Toronto, Ontario, Canada

    25 investments in total, 5 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Biotech21%
    • Healthtech & Wellness19%
    • Hardware. Robotics & IoT17%
    • Pharma7%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $1M–$3M$3M–$10M
    Based in
    Jackson, United States
    Invests in
    USA

    62 investments in total, 3 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness50%
    • Biotech19%
    • Pharma6%
    Rounds
    Seed
    Average cheque
    Not listed
    Based in
    San Francisco, United States
    Invests in
    Europe, USA, Canada

    33 investments in total, 2 tagged Pharma.Open the full fund profile

From our investor database.

Which rules trip up cannabis and psychedelic raises?

We asked 56 VCs why they pass in our Fundraising 2025 study. Revenue growth, unit economics, burn and missed milestones topped the list. Defensibility and crowded categories came next. In plant medicine, the rules add four questions of their own.

Costly loans and control terms

Cannabis owners in all eight GAO focus groups were offered loans with high fees or rates. A few met investors whose contracts could hand them control.

What investors ask

  • Who funds you if banks say no, and on what terms?

What your deck shows

  • Your capital stack: each source, its cost and its rights
  • A raise plan that keeps control with the founders

Bank fees and closed accounts

Some cannabis owners told the GAO they pay $100,000 or more a year in bank fees. Others saw accounts closed with little warning.

What investors ask

  • What happens to payroll and suppliers if your bank drops you?

What your deck shows

  • A second banking partner, and what each one costs
  • Banking costs shown in the model, not buried in overheads

Sales that rest on one country's rules

Since 29 July 2026, Germany's public health insurance no longer pays for cannabis flowers. Extracts and approved cannabinoid drugs are still covered.

What investors ask

  • How much of your revenue depends on one country's rules?

What your deck shows

  • Sales by country and by who pays
  • How fast you could move supply to another market

Prices that wait on the DEA

Part of Lilly's payment for AtaiBeckley comes only after FDA approval and DEA rescheduling. For one drug, Lilly set a seven-year deadline.

What investors ask

  • Which rule change does your valuation assume, and by when?

What your deck shows

  • Your value with and without rescheduling
  • Payments tied to each regulatory step

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Reach
60+
countries, across 90+ industries

Cannabis and psychedelics funding FAQ

How do cannabis and psychedelic companies raise money?
It depends on what you sell. Psychedelic drug developers raise as biotechs do, from venture funds, public markets and drugmakers. Lilly's purchase of AtaiBeckley in September 2026 is one example. State-licensed cannabis businesses usually can't get SBA loans, so they lean on private lenders and investors. Those loans can cost more than 15% a year. Read our term sheet guide before you sign anything.
Why won't banks work with cannabis businesses?
Does moving cannabis to Schedule III fix banking?
What is the SAFE Banking Act, and has it passed?
Do psychedelic companies face the same banking problems as cannabis?
How much does help with a cannabis or psychedelics raise cost?

Raising for a cannabis or psychedelics company?

Tell us your licences, your markets and how much you need. We'll show you what investors and lenders will check first.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?